Navigation Links
Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference

EAST NORRITON, Pa., Nov. 25 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-tissues, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion, will present at the Piper Jaffray 20th Annual Healthcare Conference on Tuesday, December 2, 2008 at 9:50 a.m. EST at The Palace Hotel in New York City, New York.

About Tengion

Tengion, a clinical stage regenerative medicine company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create neo-organs or neo-tissues that are designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information, please visit

SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Tengion Announces Second Closing of Series C Financing
2. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
3. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
4. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
5. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
6. Tengion Appoints Jeff Randall to Board of Directors
7. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
8. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
9. Sunesis to Present at Upcoming Conferences
10. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
11. EntreMed to Present at the New York Society of Security Analysts Industry Conference
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today ... December 29, 2015 at 11:00 a.m. Israel time, ... Tower, 98 Yigal Allon Street, 36 th Floor, Tel ... Eric Paneth and Izhak Tamir to the Board ... Skaliter as external directors; , approval of an amendment to certain ...
Breaking Biology Technology:
(Date:10/26/2015)... NEWARK, Calif. , Oct. 26, 2015  Delta ... convenient biometric authentication to mobile and PC devices, announced ... Fujitsu,s smartphone, the arrows NX F-02H launched by NTT ... arrows NX F-02H is the second smartphone to include ... this technology in ARROWS NX F-04G in May 2015, ...
(Date:10/23/2015)... and GOLETA, California , October ... conference, BIOPAC and SensoMotoric Instruments (SMI) announce a mobile ... tracking data captured during interactive real-world tasks ... play integration of their established wearable solutions for eye ... synchronize gaze behavior captured with SMI Eye Tracking ...
(Date:10/22/2015)...  Synaptics (NASDAQ: SYNA ), a leading developer of human ... September 30, 2015. --> --> ... 66 percent over the comparable quarter last year to $470.0 million. ... million, or $0.62 per diluted share. --> ... of fiscal 2016 grew 39 percent over the prior year period ...
Breaking Biology News(10 mins):